||Carcinogenic potential of rotenone : Phase II : Oral and intraperitoneal administration to rats /
Leber, A. P. ;
Thake, D. C.
||Battelle Columbus Labs., OH.;Health Effects Research Lab., Research Triangle Park, NC. Environmental Toxicology Div.
|| U.S. Environmental Protection Agency, Health Effects Research Laboratory ; National Technical Information Service [distributor],
||EPA/600/1-79/004; EPA-68-02-1715; EPA/600/1-79/004B
Carcinogenicity testing. ;
Parenteral infusions ;
Laboratory animals ;
Body weight ;
||Most EPA libraries have a fiche copy filed under the call number shown. Check with individual libraries about paper copy.
||vi, 39 pages : illustrations ; 28 cm
In the intraperitoneal study, test groups of male and female Sprague-Dawley rats were given daily doses of 0,1.7 or 3.0 mg/kg of rotenone for 42 days. The high rotenone dosage groups showed decrease in weight gain but there was no effect on mortality. There were numerous mammary gland neoplasms, mostly fibroadenomas, detected but they occurred with similar frequency among control and treatment groups. Except for two lymphosarcomas which occurred in high dose females, all other neoplasms were rare and/or not dosage related. In the oral study, groups of male and female Wistar rats were given daily doses of 0, 1.7 or 3.0 mg/kg of rotenone by gavage for 42 days. There were no appreciable effects of rotenone dosage on body weight, mortality, or non-neoplastic disease. Ductal ectasias and cysts were slightly more prevalent in mammary glands of dosed females as compared to controls. There was no evidence from either the intraperitoneal or oral project that rotenone induced mammary neoplasia in the rat strains studied. The significance of the slight increases in fibrosarcomas and fibromas in both the intraperitoneal and oral studies and in adrenal cortical adenomas in the oral study was inconclusive.
"EPA-600/1-79-004b." "January 1979." "PB-290 963." Microfiche.